Cambridge, United States
ARTBIO, founded in 2021 and based in the United States, is pioneering a paradigm shift in cancer treatment. Their focus on developing Alpha Radioligand Therapies (ARTs) leverages unique Pb-212 isotope technology, aiming to offer transformative solutions in oncology. The company’s mantra, “Channeling Energy. Changing Lives.,” underscores their commitment to innovation in Biotechnology, Healthcare, Medical Devices, and Pharmaceuticals.
Recently, ARTBIO secured a substantial $132.00M Series B investment on 01 July 2025, underscoring the strong investor confidence in its mission. This financial infusion was led by prominent firms such as B Capital Group, F-Prime Capital, Sofinnova Investments, Third Rock Ventures, Qatar Investment Authority, Alexandria Venture Investments, and Omega Funds. This confluence of experienced backers highlights ARTBIO's potential to redefine cancer care by making impactful therapies accessible to patients who need them most.
